Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2022)

Historic Tax Provisions for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2022 value amounting to -$5000.0.

  • Tarsus Pharmaceuticals' Tax Provisions rose 9853.37% to -$5000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was -$5000.0, marking a year-over-year increase of 9825.17%. This contributed to the annual value of -$4000.0 for FY2022, which is 10727.27% down from last year.
  • As of Q3 2022, Tarsus Pharmaceuticals' Tax Provisions stood at -$5000.0, which was up 9853.37% from $1000.0 recorded in Q1 2022.
  • In the past 5 years, Tarsus Pharmaceuticals' Tax Provisions ranged from a high of $313000.0 in Q1 2021 and a low of -$341000.0 during Q3 2021
  • Moreover, its 3-year median value for Tax Provisions was $1000.0 (2020), whereas its average is $7428.6.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Tax Provisions plummeted by 3420000.0% in 2021 and then surged by 9853.37% in 2022.
  • Quarter analysis of 3 years shows Tarsus Pharmaceuticals' Tax Provisions stood at $1000.0 in 2020, then soared by 5300.0% to $54000.0 in 2021, then tumbled by 109.26% to -$5000.0 in 2022.
  • Its Tax Provisions stands at -$5000.0 for Q3 2022, versus $1000.0 for Q1 2022 and $54000.0 for Q4 2021.